Olaparib Granted Orphan Drug Designation for Treatment of Pancreatic Cancer

The investigational therapy olaparib (Lynparza, AstraZeneca and Merck) has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of pancreatic cancer, according to an AstraZeneca press release.

There is an unmet clinical need for additional pancreatic cancer therapies, especially for patients with metastatic disease. Pancreatic cancer accounts for approximately 3% of all cancers in the United States and the 5-year survival rates for patients with the disease are 8.5%, according to the American Cancer Society. The FDA grants ODD status to medications intended for the treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 individuals in the United States.

Olaparib is currently being evaluated in the ongoing phase 3 POLO trial, which is testing the safety and efficacy of olaparib tablets (300 mg twice daily) as a maintenance monotherapy compared with placebo. The trial includes 145 patients with germline BRCA-mutated metastatic pancreatic cancer whose disease has not progressed following first-line platinum-based chemotherapy, with a primary endpoint of progression-free survival.

Olaparib is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells, according to AstraZeneca. Olaparib is also being investigated in a range of DDR-deficient tumor types.

Click to continue reading on Specialty Pharmacy Times.